Epinephrine
| Evidence Level: L5 | Predicted Indications: 54 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Epinephrine |
| DrugBank ID | DB00668 |
| Brand Names (EU) | Eurneffy |
| Evidence Level | L5 |
| Predicted Indications | 54 |
| Top Prediction Score | 99.98% |
Approved Indication (EMA)
Emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children with a body weight ≥30 kg.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | bronchitis | 99.98% | DL |
| 2 | obstructive lung disease | 99.71% | DL |
| 3 | anaphylaxis | 99.70% | DL |
| 4 | food-dependent exercise-induced anaphylaxis | 99.57% | DL |
| 5 | Rienhoff syndrome | 99.57% | DL |
| 6 | respiratory malformation | 99.56% | DL |
| 7 | pulmonary emphysema | 99.49% | DL |
| 8 | dry eye syndrome | 98.51% | DL |
| 9 | pseudoallergy | 97.32% | DL |
| 10 | laryngotracheitis | 97.31% | DL |
| 11 | headache disorder | 97.07% | DL |
| 12 | anorectal stricture | 97.02% | DL |
| 13 | trigeminal autonomic cephalalgia | 96.90% | DL |
| 14 | primary hereditary glaucoma | 96.80% | DL |
| 15 | anal polyp | 96.66% | DL |
| 16 | open-angle glaucoma | 95.72% | DL |
| 17 | tracheal disease | 95.59% | DL |
| 18 | imperforate anus | 95.50% | DL |
| 19 | bronchial neoplasm (disease) | 95.30% | DL |
| 20 | bronchial disease | 95.20% | DL |
Showing top 20 of 54 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.